TTFields Cancer Treatment Using IL11 Inhibition For Conductivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increase in IL11 expression caused by Tumor Treating Fields (TTFields) treatment leads to fibrosis, which decreases the conductivity of tumor tissue, reducing the effectiveness of TTFields by lowering power loss density, and IL11 is associated with aggressive tumor phenotypes and poor prognosis.
Innovation Solution
Inhibit IL11 activity through methods such as decreasing IL11 expression, inhibiting IL11 signaling, neutralizing IL11 with antibodies, or administering IL11 inhibitors, and use fibrosis inhibitors like fasudil or sorafenib to maintain high conductivity and enhance TTFields efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TTFields treatment is applied to cancer cells, then cancer cell growth is inhibited, but IL11 expression increases leading to fibrosis and decreased tissue conductivity
Solution Approach 1:
The patent converts the harmful effect of IL11-induced fibrosis into a beneficial outcome by using fibrosis inhibitors (such as pirfenidone, nintedanib, or fasudil) to block the fibrotic pathway. This prevents the decrease in tissue conductivity that would otherwise reduce TTFields efficacy, thereby maintaining treatment effectiveness while allowing continued TTFields application.
Solution Approach 2:
The patent applies fibrosis inhibitors in combination with TTFields treatment to preemptively counteract the fibrotic response before it can significantly reduce tissue conductivity. This preliminary anti-action ensures that the tumor microenvironment remains conductive throughout the treatment course, preventing the deterioration of TTFields efficacy that would occur with untreated fibrosis.
2Reliability
If IL11 activity is inhibited, then fibrosis is reduced and tissue conductivity is maintained, but additional treatment complexity is introduced
Solution Approach 1:
The patent introduces fibrosis inhibitors as intermediary agents that mediate between TTFields treatment and the fibrotic response. These inhibitors selectively block the IL11-driven fibrotic pathway without interfering with the primary mechanism of TTFields action, thereby maintaining tissue conductivity while adding minimal complexity to the treatment regimen through the use of established anti-fibrotic drugs.
3Power
If fibrosis inhibitors are administered, then power loss density is maintained and TTFields efficacy is enhanced, but treatment cost and complexity increase
Solution Approach 1:
The patent changes the biochemical parameters of the tumor microenvironment by inhibiting fibrosis through pharmacological agents. This prevents the increase in tissue resistance that would otherwise occur with fibrosis, thereby maintaining power loss density and TTFields efficacy without requiring changes to the TTFields delivery system or parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibiting IL11 activity and fibrosis increases the effectiveness of TTFields by maintaining high power loss density, thereby enhancing tumor treatment efficacy.
Implementation Method 1
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 500 kHz
Implementation Method 2
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 500 kHz
Implementation Method 3
inhibiting IL11 activity... use fibrosis inhibitors like fasudil or sorafenib to maintain high conductivity
Data Source
AI summary
A reduction in viability of cancer cells (e.g., glioblastoma) and a reduction in tumor volume can be achieved by applying a 100-500 kHz (e.g., 200 kHz) alternating electric field to the cancer cells and inhibiting IL11 (interleukin-11) activity and optionally administering and anti-fibrotic agent. The inhibiting of IL11 activity may be accomplished, for example, by decreasing IL11 expression, inhibiting IL11 signaling, downregulating IL11, neutralizing IL11, blocking an IL11 receptor, administering an IL11 antagonist, administering an IL11 neutralizing antibody, or administering an IL11 receptor α (IL11Ra) neutralizing antibody.